MediPharm Labs (TSE:LABS) has released an update.
MediPharm Labs Corp. has announced a strategic licensing agreement to acquire exclusive global rights for advanced medical cannabis delivery technology from Remidose Aerosols, including metered dose inhalers and aerosol sublingual sprays. This deal, expected to generate immediate revenue through the servicing of existing Remidose customers, aligns with MediPharm’s innovation strategy in non-smokable, precision-dosed cannabis products and reinforces its global leadership in the pharmaceutical and wellness-focused cannabis sectors.
For further insights into TSE:LABS stock, check out TipRanks’ Stock Analysis page.
